Stock 000411 ZHEJIANG INT'L GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang Int'l Group Co.,Ltd.

Equities

000411

CNE0000008D9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
10.71 CNY +0.09% Intraday chart for Zhejiang Int'l Group Co.,Ltd. +4.39% -4.46%
Apr. 26 Zhejiang Int'l Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 19 Zhejiang Int'l Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,622 3,030 4,824 3,743 5,814 5,856
Enterprise Value (EV) 1 3,403 3,748 5,617 4,583 6,928 6,792
P/E ratio 28.1 x 18.4 x 30.8 x 23.3 x 17.8 x 10.9 x
Yield 1.03% 0.5% 0.34% 1.36% 1.09% -
Capitalization / Revenue 0.13 x 0.12 x 0.19 x 0.14 x 0.19 x 0.18 x
EV / Revenue 0.17 x 0.15 x 0.22 x 0.17 x 0.23 x 0.21 x
EV / EBITDA 6.52 x 5.74 x 8.76 x 6.2 x 8.26 x 6.95 x
EV / FCF -23.5 x -11 x -54.9 x 35.1 x 91.1 x 62.5 x
FCF Yield -4.25% -9.11% -1.82% 2.85% 1.1% 1.6%
Price to Book 2.82 x 2 x 2.91 x 1.97 x 1.72 x 1.12 x
Nbr of stocks (in thousands) 248,941 298,729 298,729 306,368 502,465 522,434
Reference price 2 10.53 10.14 16.15 12.22 11.57 11.21
Announcement Date 4/25/19 4/25/20 4/23/21 4/19/22 4/28/23 4/19/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 20,492 24,601 25,008 26,731 30,619 32,052
EBITDA 1 522 652.6 641.4 739.1 838.4 977.3
EBIT 1 466.7 578.4 570.2 667.9 763.4 900.2
Operating Margin 2.28% 2.35% 2.28% 2.5% 2.49% 2.81%
Earnings before Tax (EBT) 1 306.6 466.1 466.4 540.6 626.2 801.4
Net income 1 93.85 151.1 156.7 167.8 212.2 488.7
Net margin 0.46% 0.61% 0.63% 0.63% 0.69% 1.52%
EPS 2 0.3750 0.5500 0.5250 0.5250 0.6500 1.030
Free Cash Flow 1 -144.7 -341.4 -102.3 130.6 76.09 108.6
FCF margin -0.71% -1.39% -0.41% 0.49% 0.25% 0.34%
FCF Conversion (EBITDA) - - - 17.67% 9.08% 11.11%
FCF Conversion (Net income) - - - 77.8% 35.85% 22.22%
Dividend per Share 2 0.1083 0.0508 0.0542 0.1666 0.1260 -
Announcement Date 4/25/19 4/25/20 4/23/21 4/19/22 4/28/23 4/19/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 781 719 792 841 1,114 936
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.497 x 1.101 x 1.235 x 1.137 x 1.329 x 0.9577 x
Free Cash Flow 1 -145 -341 -102 131 76.1 109
ROE (net income / shareholders' equity) 11.2% 13.4% 11.1% 11.8% 12.5% 13.6%
ROA (Net income/ Total Assets) 3.23% 3.66% 3.24% 3.55% 3.76% 4.16%
Assets 1 2,908 4,130 4,843 4,722 5,651 11,758
Book Value Per Share 2 3.740 5.080 5.560 6.190 6.730 10.00
Cash Flow per Share 2 6.250 5.250 6.100 6.210 2.790 3.780
Capex 1 114 137 178 189 107 168
Capex / Sales 0.56% 0.56% 0.71% 0.71% 0.35% 0.53%
Announcement Date 4/25/19 4/25/20 4/23/21 4/19/22 4/28/23 4/19/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
ZHEJIANG INT'L GROUP CO.,LTD. Stock Zhejiang Int'l Group Co.,Ltd.
-4.46% 772M
MCKESSON CORPORATION Stock McKesson Corporation
+17.35% 71.39B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+2.39% 25.1B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.38% 8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.69% 8.19B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.96% 7.91B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.49% 4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.31B
EBOS GROUP LIMITED Stock EBOS Group Limited
-3.38% 3.93B
GALENICA AG Stock Galenica AG
-2.61% 3.86B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 000411 Stock
  4. Financials Zhejiang Int'l Group Co.,Ltd.